The role of dopamine for the pathophysiology of schizophrenia

References

• Abler B, Erk S, Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology 2007; 191: 823–33
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort. American Journal of Psychiatry 1998; 155: 761–767
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2000; 97(14)8104–9
   PubMed Web of Science ®Google Scholar
• Bannon MJ, Sacchetti P, Granneman JG. The dopamine transporter: potential involvement in neuropsychiatric disorders. Psychopharmacology. the fourth generation of progress, Online Edition, F. E. Bloom, D. J. Kupfer. Raven Press, New York 2000; 134–138
   Google Scholar
• Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2001; 11: 449–55
   PubMed Web of Science ®Google Scholar
• Baracskay KL, Haroutunian V, Meador-Woodruff JH. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. 2006; 60(4)271–9
   Google Scholar
• Berridge KC. Food reward: Brain substrates of wanting and liking. Neuroscience and Biobehavioral Reviews 1996; 20: 1–25
   PubMed Web of Science ®Google Scholar
• Bonci A, Grillner P, Siniscalchi A, Mercuri NB, Bernardi G. Glutamate metabotropic receptor agonists depress excitatory and inhibitory transmission on rat mesencephalic principal neurons. The European Journal of Neuroscience 1997; 9: 2359–2369
   PubMed Web of Science ®Google Scholar
• Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 1997; 94(6)2569–74
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research 2006; 85: 232–244
   PubMed Web of Science ®Google Scholar
• Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, et al. Long-term treatment of rats with haloperidol: Lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 2006; 31: 751–756
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia – therapeutic implications. Brain Research Brain Research Reviews 2000; 31: 342–349
   PubMedGoogle Scholar
• Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annual Review of Pharmacology and Toxicology 2001; 41: 237–60
   PubMed Web of Science ®Google Scholar
• Chan P, Langston JW, Di Monte DA. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. The. Journal of Pharmacology and Experimental Therapeutics 1993; 267: 1515–20
   PubMed Web of Science ®Google Scholar
• Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, Buchsbaum MS, et al. Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage 2006; 31: 139–152
   PubMed Web of Science ®Google Scholar
• Ciliax BJ, Heilman C, Demechyshyn LL, Pristupa ZB, Ince E, Hersch SM, et al. The dopamine transporter: Immunochemical characterization and localization in brain. The Journal of neuroscience: The official journal of the Society for Neuroscience 1995; 15: 1714–23
   PubMed Web of Science ®Google Scholar
• Cragg SJ, Rice ME. Dancing past the DAT at a DA synapse. Trends in Neurosciences 2004; 27: 270–277
   PubMed Web of Science ®Google Scholar
• Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research 1997; 23: 167–74
   PubMed Web of Science ®Google Scholar
• De Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: Clinical implications. Canadian Journal of Psychiatry 2004; 49: 290–296
   PubMed Web of Science ®Google Scholar
• De Haan L, Lavalaye J, Booij J, Linszen D. Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics. American Journal of Psychiatry 2005; 162: 1544–1545
   PubMed Web of Science ®Google Scholar
• Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2001; 98(12)6917–22
   PubMed Web of Science ®Google Scholar
• El-Ghundi M, O'Dowd BF, George SR. Insights into the role of dopamine receptor systems in learning and memory. Reviews in the neurosciences 2007; 18: 37–66
   PubMed Web of Science ®Google Scholar
• Ferry AT, Ongur D, An X, Price JL. Prefrontal cortical projections to the striatum in macaque monkeys: Evidence for an organization related to prefrontal networks. The Journal of Comparative Neurology 2000; 425: 447–470
   PubMed Web of Science ®Google Scholar
• Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biological Psychiatry 2006; 60: 621–629
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. Regional and cellular fractionation of working memory. Proceedings of the National Academy of Sciences of the United States of America 1996; 93(24)13473–80
   PubMed Web of Science ®Google Scholar
• Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research Brain Research Reviews 2000; 31: 330–341
   PubMed Web of Science ®Google Scholar
• Grace AA. Psychostimulant action on dopamine and limbic system function: Relevance to the pathophysiology and treatment of ADHD. Stimulant drugs and ADHD: Basic and clinical neuroscience, M. V. Solanto, A. F. T. Arnsten, F. X. Castellanos. Oxford University Press, New York 2001; 134–157
   Google Scholar
• Grace A. A. Dopamine. Neuropsychopharmacology. The Fifth Generation of Progress. An Official Publication of the American College of Neuropsychopharmacology, K. L. Davis, D. Charney, C. Nemeroff. Lippincott Williams & Wilkins, Philadelphia 2002; 120–132
   Google Scholar
• Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: Burst firing. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 1984; 4: 2877–2890
   PubMed Web of Science ®Google Scholar
• Grillner P, Bonci A, Svensson TH, Bernardi G, Mercuri NB. Presynaptic muscarinic (M3) receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon. Neuroscience 1999; 91: 557–565
   PubMed Web of Science ®Google Scholar
• Grillner P, Berretta N, Bernardi G, Svensson TH, Mercuri NB. Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. Neuroscience 2000; 96: 299–307
   PubMed Web of Science ®Google Scholar
• Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of Dopamine in Schizophrenia. International Review of Neurobiology 2007; 78: 1–41
   PubMed Web of Science ®Google Scholar
• Harte MK, Bachus SB, Reynolds GP. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophrenia Research 2005; 75: 303–308
   PubMed Web of Science ®Google Scholar
• Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grässer SM, et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. American Journal of Psychiatry 2004; 161: 1783–9
   PubMed Web of Science ®Google Scholar
• Hietala J, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130–1
   PubMed Web of Science ®Google Scholar
• Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC. Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1. Schizophrenia Research 2003; 65: 39–46
   PubMed Web of Science ®Google Scholar
• Joel D, Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000; 96: 451–474
   PubMed Web of Science ®Google Scholar
• Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wüstenberg T, Villringer A, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 2006a; 187: 222–228
   PubMed Web of Science ®Google Scholar
• Juckel G, Schlagenhauf F, Koslowski M, Wüstenberg T, Villringer A, Knutson B, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006; 29: 409–416
   PubMed Web of Science ®Google Scholar
• Kienast T, Heinz A. Dopamine and the diseased brain. CNS & Neurological Disorders Drug Targets 2006; 5: 109–31
   PubMedGoogle Scholar
• Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. Journal of Neurosciences 2001; 21: RC159
   PubMed Web of Science ®Google Scholar
• Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Archives of General Psychiatry 2003; 60: 311–9
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science 1997; 278: 52–8
   PubMed Web of Science ®Google Scholar
• Krawczyk DC, Gazzaley A, Desposito M. Reward modulation of prefrontal and visual association cortex during an incentive working memory task. Brain Research 2007; 13, 1141: 168–77
   Web of Science ®Google Scholar
• Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, et al. Striatal Dopamine Transporter Binding in Neuroleptic-Naive Patients with Schizophrenia Studied with Positron Emission Tomography. American Journal of Psychiatry 2000; 157: 269–271
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 9235–9240
   PubMed Web of Science ®Google Scholar
• Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17: 162–74
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biological Psychiatry 1999; 46: 56–72
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck C, Gil R, DáSouza DC, Krystal J, et al. Dopamine and Serotonin Transporters in Patients with Schizophrenia: An Imaging Study with [123I]ß-CIT. Biological Psychiatry 2000; 47: 371–379
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Linszen DH, Booij J, Dingemans P. M. A. J., Reneman L, Habraken JBA, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizophrenia Research 2001; 47: 59–67
   PubMed Web of Science ®Google Scholar
• Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biological Psychiatry 1999; 46: 681–8
   PubMed Web of Science ®Google Scholar
• Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 2000; 43: 355–358
   PubMed Web of Science ®Google Scholar
• Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 1996; 15: 17–29
   PubMed Web of Science ®Google Scholar
• Meisenzahl EM, Dresel S, Frodl T, Schmitt GJ, Preuss UW, Rossmuller B, et al. D2 receptor occupancy under recommended and high doses of olanzapine: An iodine-123-iodobenzamide SPECT study. Journal of Psychopharmacology 2000; 14: 364–70
   PubMed Web of Science ®Google Scholar
• Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, et al. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: A functional MRI follow-up investigation. European Archives of Psychiatry and Clinical Neurosciences 2006; 256: 522–31
   PubMed Web of Science ®Google Scholar
• Mercuri NB, Grillner P, Bernardie G. N-methyl-D-aspartate receptors mediate a slow excitatory postsynaptic potential in the rat midbrain dopaminergic neurons. Neuroscience 1996; 74: 785–792
   PubMed Web of Science ®Google Scholar
• Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia. American Journal of Psychiatry 2007; 164: 630–637
   PubMed Web of Science ®Google Scholar
• Mueller U, von Cramon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. Journal of Neurosciences 1998; 8: 2720–8
   Google Scholar
• Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kervin RW. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. British Journal of Psychiatry 1994; 163: 833–4, Erratum in: British Journal of Psychiatry, 1994 Feb; 164:270
   Web of Science ®Google Scholar
• Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proceedings of the National Academy of Sciences of the United States of America 1994; 91(24)11651–4
   PubMed Web of Science ®Google Scholar
• Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: Molecular, cellular, functional and behavioral abnormalities. Biological Psychiatry 2006; 59: 721–9
   PubMed Web of Science ®Google Scholar
• Rowland L, Bustillo JR, Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Seminars in Clinical Neuropsychiatry 2001; 6: 121–130
   PubMedGoogle Scholar
• Richfield EK, Penney JB, Young AB. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience 1989; 30: 767–777
   PubMed Web of Science ®Google Scholar
• Schmitt GJE, Frodl T, Tatsch K, Dresel S, Möller H-J., Meisenzahl EM. Striatal dopamine transporter in drug-naive schizophrenic patients: A 99mTc-TRODAT-1-SPECT-Study. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2000; 10(Suppl 3)324
   Google Scholar
• Schmitt GJE, Frodl T, Dresel S, Möller H-J., Meisenzahl EM. Striatal Dopaminergic Synapses in Drug Naive Schizophrenics. The World Journal of Biological psycHiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 2001; 2(Supplement 1)93S
   Google Scholar
• Schmitt GJE, Meisenzahl EM, Frodl T, la Fougère C, Hahn K, Möller H-J., et al. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: Evaluation by the new SPECT-ligand [99mTc]TRODAT-1. Journal of Psychopharmacology 2005; 19: 488–93
   PubMed Web of Science ®Google Scholar
• Schmitt GJE, Frodl T, Dresel S, la Fougère C, Bottlender R, Koutsouleris N, et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. European Archives of Psychiatry and Clinical Neurosciences 2006; 256: 115–121
   PubMed Web of Science ®Google Scholar
• Schmitt GJE, Meisenzahl EM, Frodl T, La Fougère C, Hahn K, Möller H-J, et al. Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [123I]IBZM SPECT. Psychiatry Research: Neuroimaging 2007, (in revision)
   Web of Science ®Google Scholar
• Schmitt GJE, la Fougère C, Dresel S, Frodl T, Hahn K, Möller H-J, et al. Dual-isotope SPECT imaging of striatal dopamine in first-episode, drug naïve schizophrenic patients. Schizophrenia Research 2007, (submitted)
   Web of Science ®Google Scholar
• Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, et al. Dopamine supersensitivity correlates with D2High states, implying many path to psychosis. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 3513–3518
   PubMed Web of Science ®Google Scholar
• Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert opinion on therapeutic targets 2006; 10: 515–531
   PubMed Web of Science ®Google Scholar
• Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. Journal of Neurosciencs 1998; 18: 2697–2708
   PubMed Web of Science ®Google Scholar
• Smolders I, De Klippel N, Sarre S, Ebinger G, Michotte Y. Tonic GABAergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. European Journal of Pharmacology 1995; 284: 83–91
   PubMed Web of Science ®Google Scholar
• Suhara T, Okubo Y, Yasuno F, Sodo Y, Inoue M, Ichimiya T, et al. Decreased Dopamine D2 Receptor Binding in the Anterior Cingulate Cortex in Schizophrenia. Archives of General Psychiatry 2002; 59: 25–30
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kato M, Hayashi M, Okubo Y, Takano A, Ito H, et al. Memory and frontal lobe functions: Possible relations with dopamine D2 receptors in the hippocampus. Neuroimage 2007; 34: 1643–1649
   PubMed Web of Science ®Google Scholar
• Tuppurainen H, Kuikka J, Vilnamäki H, Husso-Saastamoinen M, Bergström K, Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naïve schizophrenic patients. Molecular Psychiatry 2003; 8: 453–455
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Geyer MA. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Research Bulletin 2001; 56: 495–507
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 24;386: 830–3
   Web of Science ®Google Scholar
• Waelti P, Dickinson A, Schultz W. Dopamine responses comply with basic assumptions of formal learning theory. Nature 2001; 412: 43–8
   PubMed Web of Science ®Google Scholar
• Wise RA. Neurobiology of addiction. Current Opinion in Neurobiology 1996; 6: 243–51
   PubMed Web of Science ®Google Scholar
• Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987; 44: 660–9
   PubMed Web of Science ®Google Scholar
• Wolf ME, Dahlin SL, Hu XT, Xue CJ, White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioural sensitization to amphetamine: Comparison with N-methyl-D-aspartate antagonists. Neuroscience 1995; 69: 417–439
   PubMed Web of Science ®Google Scholar
• Yang YK, Yu L, Yeh LY, Chiu NT, Chen PS, Lee IH. Associated Alterations of Striatal Dopamine D2/D3 Receptor and Transporter Binding in Drug-Naïve Patients With Schizophrenia: A Dual-Isotope SPECT Study. American Journal of Psychiatry 2004; 161: 1496–1498
   PubMed Web of Science ®Google Scholar